Oct. 28, 2020 |
|
Mar. 30, 2022 |
|
jRCT2031200177 |
Post-marketing clinical trial of Pemafibrate in patients with impaired renal function |
|
PALT02 |
Ishibashi Shun |
||
Jichi Medical University |
||
3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, Japan |
||
+81-3-3279-7454 |
||
ctrdinfo@kowa.co.jp |
||
Sogabe Yukihisa |
||
Kowa Company, Ltd. |
||
4-14, Nihonbashi-honcho 3-chome, Chuo-ku, Tokyo |
||
+81-3-3279-7454 |
||
ctrdinfo@kowa.co.jp |
Complete |
Aug. 27, 2020 |
||
Sept. 08, 2020 | ||
20 | ||
Interventional |
||
randomized controlled trial |
||
double blind |
||
placebo control |
||
parallel assignment |
||
treatment purpose |
||
1) Dyslidemia : Fasting Serum TG>=150mg/dL |
||
1) Patients with severe liver damage, cirrhosis or biliary atresia patient |
||
20age old over | ||
No limit | ||
Both |
||
Dyslidemia |
||
0.1mg, twice a day, oral |
||
Pharmacokinetic parameter (AUC) |
||
Kowa Company, Ltd. |
Review Board of Human Rights and Ethics for Clinical Studies | |
13-2 Ichibancho, Chiyoda-ku, Tokyo | |
+81-3-5213-0028 |
|
info@hurecs.org | |
Approval | |
July. 20, 2020 |
No |
|
none |